These characteristics of SGLT2 inhibitors are completely different from erythropoiesis-stimulating agents (ESAs), which are commonly used to treat anemia in patients with chronic kidney disease (CKD) and increase the risk of mortality or cardiovascular events at high doses [7, 8]. Here, SLC5A2 is linked to anemia.